Seven of 67 patients who received the cerebral adrenoleukodystrophy gene therapy developed blood cancer, though most cases ...

The firm is gearing up for a registration-directed trial based on a positive Phase Ib readout and after discussions with US ...

The drugmaker wants to establish Enhertu in HER2-ultralow breast cancer and even HER2-negative tumors but remains committed to precision medicine strategies.

In a post hoc analysis within a prior Phase II study, the company found SP-624 improved symptoms in female patients with major depressive disorder.

In the INAVO120 trial, Itovebi added to Pfizer's Ibrance and fulvestrant doubled progression-free survival versus Ibrance and fulvestrant alone.

The firm plans to use the proceeds to advance its pipeline of T-cell receptor therapies and support their manufacturing, production, and commercialization.

The firm will use the court-administered restructuring process to pursue strategic alternatives so it can continue developing vaccines and immunotherapies.

Researchers will develop therapies for urea cycle disorders and create a platform to rapidly develop treatments for other rare genetic disorders.

Immatics raised $175 million in a previous public stock offering earlier this year, and $110 million in a previous private stock offering in October 2022.

The firm is evaluating leniolisib, which is already approved and sold under the brand name Joenja for APDS, in certain primary immunodeficiencies with immune dysregulation.

Editas will receive $57 million in upfront cash from DRI Healthcare Trust in exchange for certain future licensing fees and ...

The London-based firm said it will use the funds to advance its gene therapy pipeline, including its lead program in IgA nephropathy.